Drugs / ATH-063
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05807971 | Apr 2023 → Feb 2024 | Crohn disease, autoimmune disease, ulcerative colitis | Athos Therapeutics Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07513181 | Jun 2026 → Dec 2028 expected | autoimmune disease, ulcerative colitis | Athos Therapeutics Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATH-063 | “The goal of this clinical trial is to test the ATH-063 drug (single and multiple doses) in Healthy Subjects.” NCT05807971 ↗ |
| Route | Oral | “receive a single oral dose of ATH-063 (capsule) under fasting conditions at the planned dose levels.” NCT05807971 ↗ |